Damora Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
DMRA$24.07+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets · (unaudited) | ||
| Current assets | ||
| Cash and cash equivalents | $11,939 | $14,175 |
| Prepaid expenses and other current assets | 2,984 | 2,664 |
| Total current assets | 14,923 | 16,839 |
| Operating lease right-of-use asset | 73 | 73 |
| Equipment, net | 52 | 57 |
| Other assets, noncurrent | 317 | 163 |
| Total assets | $15,365 | $17,132 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $354 | $377 |
| Accrued expenses and other current liabilities | 1,197 | 820 |
| Total current liabilities | 1,551 | 1,197 |
| Operating lease liabilities, noncurrent | 60 | 61 |
| Other liabilities, noncurrent | 45 | 43 |
| Total liabilities | 1,656 | 1,301 |
| Commitments and contingencies (Note 8) | ||
| Mezzanine equity | ||
| Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at March 31, 2025 and December 31, 2024; 161 shares issued and outstanding as of March 31, 2025 and December 31, 2024 | 1,360 | 1,360 |
| Stockholders’ equity | ||
| Common stock, par value of $0.00001 per share; 300,000,000 shares authorized at March 31, 2025 and December 31, 2024; 1,322,359 and 1,316,989 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | — | — |
| Additional paid-in capital | 292,106 | 291,898 |
| Accumulated deficit | (280,057) | (277,524) |
| Accumulated other comprehensive income | 300 | 97 |
| Total stockholders’ equity | 13,709 | 15,831 |
| Total liabilities and stockholders' equity | $15,365 | $17,132 |
Galecto, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.